Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1695202 | 0.95 | TP53 (0.60) | FAAHLMNAALDH1A1 | |
| SCHEMBL15514715 | 0.86 | NPC1 (0.66) | LMNASMN1; SMN2 | |
| SCHEMBL29982783 | 0.85 | TSHR (0.54) | FAAHLMNAALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL594607 | 0.85 | GAA (0.51) | FAAHLMNAALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL31366715 | 0.84 | FAAH (0.52) | FAAH | |
| SCHEMBL17935564 | 0.84 | NPC1 (0.68) | LMNAALDH1A1SMN1; SMN2KDM4ECYP1A2 | |
| SCHEMBL2568470 | 0.84 | FAAH (0.55) | FAAHLMNACYP2D6 | |
| SCHEMBL23755008 | 0.83 | HRH3 (0.60) | LMNAALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL28275379 | 0.83 | MAPK1 (0.60) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL9308211 | 0.83 | FAAH (0.63) | FAAHLMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1472215-A4 | (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-05-09 | — | — | EP | disclosed |
| US-6949574-B2 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050131032-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | SIT SING-YUEN (US) | 2005-06-16 | — | — | US | disclosed |
| EP-1472215-A2 | (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20030195226-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | SIT SING-YUEN (US) | 2003-10-16 | — | — | US | disclosed |
| WO-2003065989-A2 | (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195226-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | FAAH, FAAH2, NCEH1 | FAAH 1/4885LMNA 4276/4885ALDH1A1 394/4885 |
| US-20050131032-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | FAAH, FAAH2, NCEH1 | FAAH 1/4885LMNA 4276/4885ALDH1A1 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.